• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


British-Based AstraZeneca Plans Rockville, Maryland, Manufacturing Operations

Global science-led biopharmaceutical company AstraZeneca plans to establish manufacturing operations in Rockville, Maryland. The $300 million project is expected to create 150 jobs in Montgomery County.

The new 84,000-square-foot facility, located on 9950 Medical Center Drive and less than five miles from one of the company’s research and development centers, will initially focus on the manufacturing of CAR-T cell therapies to enable cancer clinical trials to be conducted around the world. Production is currently scheduled for 2026.

“We are incredibly excited that more than 150 new highly skilled jobs are being created to bring our scientific work and therapies to clinical trials which could transform the lives of patients around the world,” said AstraZeneca Executive Vice President of Global Operations & IT and Chief Sustainability Officer Pam Cheng. “This new $300 million investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients.”

To assist with project costs, the Maryland Department of Commerce is working to approve a $500,000 conditional loan through the Advantage Maryland program. Montgomery County is planning to provide a $100,000 conditional grant through its Economic Development Fund. The company is also eligible for various other incentives, including the More Jobs for Marylanders program and the state's Job Creation Tax Credit.

“While Maryland's pool of talented life science professionals continues to grow, so does the amount of career opportunities in the industry. We are very grateful to AstraZeneca for planning to bring approximately 150 new jobs to Montgomery County over the next few years,” noted Maryland Department of Commerce Secretary Kevin Anderson. “We look forward to watching this facility become a major player for the company and the life sciences community in Maryland.”

AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology. The company operates in more than 100 countries.

"Montgomery County is at the epicenter of cell and gene therapy, anchoring the third largest life sciences hub in the U.S.,” added Montgomery County Economic Development Corporation (MCEDC) President and Chief Executive Officer Bill Tompkins. “We are home to innovation and life-saving treatments that make a positive global impact. And we are thrilled that AstraZeneca continues to grow and invest in new technologies here in Montgomery County, which will ultimately lead to greater economic viability for our region. We join Governor Moore, County Executive Elrich, and all of our partners and stakeholders in congratulating AstraZeneca for their continued expansion.”

Exclusive Research